Article

Tobacco industry, meet the FDA

Author(s):

It's official: The tobacco industry now has to play by new rules. Referencing his own struggles to quit smoking, President Obama signed into law on Monday a bill that gives the Food and Drug Administration the power to regulate tobacco products that are responsible for nearly one in five deaths in the U.S.The Family Smoking Prevention and Tobacco Control Act gives the FDA authority over how tobacco products are manufactured and sold. During the coming months and years, a number of changes and regulations (check out a breakdown by The Associated Press) will be put into place. These include removal of flavored cigarettes from the market, a ban on tobacco-brand sponsorships of sports and entertainment events, larger and stronger warning labels on all tobacco products, and premarket approval from the FDA of all new tobacco products.That last one sounds funny, doesn't it? The FDA will approve new tobacco products. I guess "FDA-approved" just took on dual meaning.Like most things, neither side is completely happy. Anti-smoking advocates say the bill doesn't go far enough to prevent smoking. (The bill doesn't ban nicotine, the ingredient that actually makes you addicted. Nor does it ban the products themselves. You'll still find cigarettes, smokeless tobacco, cigars and other products on store shelves.) And opponents say the law's ban on outdoor advertising within 1,000 feet of schools and playgrounds restricts free speech. Catch Obama talking about the law here.

Related Videos
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Image of Dr. Salani.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Fakih.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
Dr. Gabriel A. Brooks discussed the recent FDA product labeling update for Xeloda and 5-FU.
1 expert is featured in this series.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Related Content